Economic Evaluation Of Dabigatran Etexilate Versus Warfarin, Rivaroxaban And Apixaban In Stroke Prevention In Atrial Fibrilation
May 1, 2015, 00:00 AM
10.1016/j.jval.2015.03.819
https://www.valueinhealthjournal.com/article/S1098-3015(15)00876-1/fulltext
Section Title :
Cardiovascular Disorders
Section Order :
260
First Page :
A141
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(15)00876-1&doi=10.1016/j.jval.2015.03.819